Results 1 to 10 of about 46,021 (50)

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study

Journal of glaucoma, 2022
Précis: NCX 470 0.042% and 0.065% were statistically superior in intraocular pressure (IOP) lowering to latanoprost 0.005%, and NCX 470 0.021% was noninferior. All NCX 470 concentrations were safe and well tolerated.
T. Walters, Angela C Kothe, J. Boyer, D. Usner, Krisol Lopez, B. Duquesroix, R. Fechtner, Tomas Navratil   +7 more
semanticscholar   +1 more source

Berberine Suppresses Mice Depression Behaviors and Promotes Hippocampal Neurons Growth Through Regulating the miR-34b-5p/miR-470-5p/BDNF Axis

Neuropsychiatric Disease and Treatment, 2021
Background Berberine has been found to inhibit the progression of depression disorder, but its specific mechanism is still unclear. MicroRNA (miRNA) is considered to play an important role in the progression of depression.
Yuhua Zhan, Jiyang Han, Jing Xia, Xumei Wang   +3 more
semanticscholar   +1 more source

Patient characteristics and predictors of mortality in 470 adults admitted to a district general hospital in England with Covid-19

Epidemiology and Infection, 2020
Understanding risk factors for death from Covid-19 is key to providing good quality clinical care. We assessed the presenting characteristics of the ‘first wave’ of patients with Covid-19 at Royal Oldham Hospital, UK and undertook logistic regression ...
J. Thompson, N. Meghani, B. Powell, I. Newell, R. Craven, G. Skilton, L. J. Bagg, I. Yaqoob, M. Dixon, E. Evans, B. Kambele, Aziz Ur Rehman, G. Ng Man Kwong   +12 more
semanticscholar   +1 more source

PGK1 inhibitor CBR-470-1 protects neuronal cells from MPP+

Aging, 2020
The neurotoxin MPP+ (1-methyl-4-phenylpyridinium ion) disrupts mitochondrial function leading to oxidative stress and neuronal death. Here we examine whether activation of the Keap1-Nrf2 cascade can protect SH-SY5Y neuroblastoma cells from MPP+-induced ...
Jin-yu Zheng, Jian-liang Zhu, Yufeng Zhang, Hao Zhang, Yu Yang, De-Rong Tang, Jian Sun   +6 more
semanticscholar   +1 more source

Deep 230-470 MHz VLA observations of the mini-halo in the Perseus cluster [PDF]

, 2017
We present a low-frequency view of the Perseus cluster with new observations from the Karl G. Jansky Very Large Array (JVLA) at 230–470 MHz. The data reveal a multitude of new structures associated with the mini-halo. The mini-halo seems to be influenced
M. Gendron-Marsolais, J. Hlavacek-Larrondo, R. Weeren, Tracy E. Clarke, A. Fabian, H. Intema, G. Taylor, K. Blundell, J. Sanders   +8 more
semanticscholar   +1 more source

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients

Journal of the European Academy of Dermatology and Venereology, 2018
Chronic spontaneous urticaria (CSU) is defined as spontaneous occurrence of wheals and/or angioedema for ≥6 weeks. Omalizumab is a monoclonal anti‐IgE antibody effective in refractory CSU, but its mechanism of action and markers predictive of response ...
Angelo V. Marzano, Angelo V. Marzano, Giovanni Genovese, Giovanni Genovese, Giovanni Casazza, M. Fierro, P. Dapavo, N. Crimi, S. Ferrucci, Patrizia Pepe, S. Liberati, P. D. Pigatto, A. Offidani, E. Martina, G. Girolomoni, M. Rovaris, Caterina Foti, Luca Stingeni, Antonio Cristaudo, G. Canonica, Eustachio Nettis, R. Asero   +21 more
semanticscholar   +1 more source

AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial.

Journal of Crohn's & Colitis, 2016
BACKGROUND AND AIMS AVX-470 is an oral, polyclonal bovine-derived anti-tumour necrosis factor (TNF) antibody in development for treatment of inflammatory bowel disease (IBD).
M. Harris, D. Hartman, Brenda R Lemos, E. Erlich, S. Spence, Sally Kennedy, Theadore Ptak, R. Pruitt, S. Vermeire, B. Fox   +9 more
semanticscholar   +1 more source

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report

Frontiers in Immunology, 2018
The allogeneic therapeutic vaccine CSF-470 has demonstrated a significant benefit over medium-dose IFNα2b in the distant metastasis-free survival for stages IIB–IIC–III cutaneous melanoma patients in a randomized phase II/III clinical trial (CASVAC-0401,
Mariana Aris, A. Bravo, M. Pampena, P. Blanco, Ibel Carri, D. Koile, P. Yankilevich, E. Levy, M. M. Barrio, J. Mordoh   +9 more
semanticscholar   +1 more source

Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants

Frontiers in Immunology, 2018
As cutaneous melanoma (CM) currently remains with a bleak prognosis, thorough investigation of new treatment options are of utmost relevance. In the phase II/III randomized clinical trial (CASVAC-0401), the repeated immunization of stages IIB-III CM ...
M. Pampena, Holliday Cartar, G. Cueto, E. Levy, P. Blanco, M. M. Barrio, J. Mordoh   +6 more
semanticscholar   +1 more source

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study

Frontiers in Immunology, 2017
The irradiated, allogeneic, cellular CSF-470 vaccine plus Bacillus Calmette–Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) is being tested against medium-dose IFN-α2b in stages IIB–III cutaneous melanoma ...
J. Mordoh, M. Pampena, Mariana Aris, P. Blanco, M. Lombardo, Erika von Euw, Soledad Mac Keon, Michelle Yépez Crow, A. Bravo, J. O'Connor, Ana Gabriela Orlando, F. Ramello, E. Levy, M. M. Barrio   +13 more
semanticscholar   +1 more source